Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.
about
Warfarin Pharmacogenetics: New Life for an Old DrugEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationThe Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyCurrent issues in anticoagulation.Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.Pharmacogenetics of warfarin: challenges and opportunities.Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.In Silico Design of Novel Anticoagulant Peptides targeting Blood Coagulation Factor VIIa.The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects.Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.Apixaban: an oral direct factor-xa inhibitor.Prediction of warfarin dose: why, when and how?Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.Evaluation of Potential Thrombin Inhibitors from the White Mangrove (Laguncularia racemosa (L.) C.F. Gaertn.).Role of ABC transporters in trans-epithelial transport of vitamin K antagonists.Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs.Clinical risks of St John's Wort (Hypericum perforatum) co-administration.Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects.Antiplatelet and Anticoagulant Activities of Angelica shikokiana Extract and Its Isolated Compounds.Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery.
P2860
Q28468726-C9CC78BD-0F97-4383-9DCD-3B2FA6F1F955Q28477868-84371BCD-964C-4958-B426-29A0340EBBDCQ28553937-3D6249C1-802B-4DC4-9B41-CE60C03F9F9EQ33365707-9E8E06F8-524E-45CE-A8F1-BFB764C5A1D3Q33795072-98E7E9DF-2CF3-4C57-AC41-824003A3B33AQ33819050-53FD41B1-F8AF-4341-B23B-A41157F2A006Q34019240-219EA82E-FB51-4A91-AF7D-5EEC0E496AB4Q34627780-41AF81F3-B991-4A35-807F-F25DEE8A5E99Q34782370-5454F6CF-FE1C-4C50-AFC7-212C360C6A98Q35640455-B5438CD3-B502-4C0C-A1DE-7967AF8444B3Q35725540-D9A34E45-DB6E-478E-9E37-35E342B4E5A0Q36304924-07E247A9-F707-4975-BB47-A3B2B0A548EFQ36842490-A550043B-F7BE-49FA-8D4C-D5CE71AC29D1Q37832976-73BC075B-17F3-4CB0-95E6-8528B6B6A6A0Q37987051-BA5741F7-51F1-4944-A706-2FD9C993A47AQ37989489-D024F30F-76AF-4514-887F-C28416E4E3E7Q38148597-8960E387-8645-461B-9149-0CA49C602549Q38336950-1916AA71-5F2F-4FEC-AA24-D6F165CB6360Q39247505-FF211759-8AB8-41EF-834D-7D5DCED9C068Q39537454-6752E5DB-5EFA-427C-A190-789AF9E6D95EQ41686238-4601EACA-33B3-4ED3-8C97-9E1798644C74Q41823356-CC130FB8-807B-4FA7-933D-A6654DA1F890Q42391725-3D07C2BD-0461-45AD-916F-DD59F440837EQ42502722-4CC26592-1016-4017-A765-91B29CE52C2DQ43176747-DE7C677A-D87E-41E3-A81F-B4DD93CAD937Q47774682-5DD8BF9F-1F68-473D-93BA-B16921933D1EQ47999149-58F7767C-3AE6-4D90-AF4D-0525B87F8D12Q50634411-3B7F62B5-CB91-4590-B787-6872351DF823Q50918683-73EAA12B-B4C3-4035-AE77-4D5B8A17AAF8Q52814257-419BDFD0-B9D4-4B3A-90B9-781AE4A37AC5Q53082987-80EB6EFF-926A-4882-9761-0DC7A50A23E3Q53425138-38B7308A-8CC9-4286-AAA8-DDCF99A32663Q55129512-82E36F6F-598A-4933-844F-924795B74810
P2860
Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Warfarin and other coumarin de ...... namics, and drug interactions.
@ast
Warfarin and other coumarin de ...... namics, and drug interactions.
@en
type
label
Warfarin and other coumarin de ...... namics, and drug interactions.
@ast
Warfarin and other coumarin de ...... namics, and drug interactions.
@en
prefLabel
Warfarin and other coumarin de ...... namics, and drug interactions.
@ast
Warfarin and other coumarin de ...... namics, and drug interactions.
@en
P356
P1476
Warfarin and other coumarin de ...... namics, and drug interactions.
@en
P2093
Ann K Wittkowsky
P304
P356
10.1055/S-2003-44457
P577
2003-08-01T00:00:00Z